Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes.

Trial Profile

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs Liraglutide (Primary) ; Metformin (Primary) ; Lixisenatide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LIRA-LIXI
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2016 Results published in the Diabetes Care
    • 16 Sep 2015 According to Novo Nordisk media release, results were presented in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top